FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab developed by mAbxience

MIAMI, May 2, 2022 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with mAbxience developing the brand name ALYMSYS, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed by Amneal Pharmaceuticals LLC.